ArticleFrontiers in physiology2021
Urinary Metabolites as Predictors of Acute Mountain Sickness Severity.
Article in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Biomarkers and potential subtypes of acute mountain sickness: A state-of-the-science review.Redox biology · 2026Review
- Article
- Susceptibility to mild and severe acute mountain sickness is associated with distinct urine metabolite profiles.Frontiers in physiology · 2026Article
- Metabolomics Signatures of a Respiratory Tract Infection During an Altitude Training Camp in Elite Rowers.Metabolites · 2025Article
- Urine metabolite profiling in Indian males exposed to high-altitude: a longitudinal pilot study.Scientific reports · 2025Article
- Metabolic insights into hypoxia adaptation in adolescent athletes at different altitudes: a cross-sectional study.Frontiers in molecular biosciences · 2025Article
- [Status of Research on Molecular Mechanisms and Management of Acute Mountain Sickness].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- A global view on quantitative proteomic and metabolic analysis of rat livers under different hypoxia protocols.Heliyon · 2024Article
- Rapid altitude displacement induce zebrafish appearing acute high altitude illness symptoms.Heliyon · 2024Article
- Recent advances in predicting acute mountain sickness: from multidimensional cohort studies to cutting-edge model applications.Frontiers in physiology · 2024Review
- AZU1 (HBP/CAP37) and PRKCG (PKC-gamma) may be candidate genes affecting the severity of acute mountain sickness.BMC medical genomics · 2023Article
- A sportomics soccer investigation unveils an exercise-induced shift in tyrosine metabolism leading to hawkinsinuria.Frontiers in nutrition · 2023Article
- Metabolomic and Proteomic Identification of Serum Exosome for Hypoxic Preconditioning Participants.Oxidative medicine and cellular longevity · 2023Article
- Metabolomic analysis of human plasma sample after exposed to high altitude and return to sea level.PloS one · 2023Article
- High Intensity Concentric-Eccentric Exercise Under Hypoxia Changes the Blood Metabolome of Trained Athletes.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals sojourning at high altitude (≥2,500m) often develop acute mountain sickness (AMS). However, substantial unexplained inter-individual variability in AMS severity exists. Untargeted metabolomics assays are increasingly used to identify novel biomarkers of susceptibility to illness, and to elucidate biological pathways linking environmental exposures to health outcomes. This study used untargeted nuclear magnetic resonance (NMR)-based metabolomics to identify urine metabolites associated with AMS severity during high altitude sojourn. Following a 21-day stay at sea level (SL; 55m), 17 healthy males were transported to high altitude (HA; 4,300m) for a 22-day sojourn. AMS symptoms measured twice daily during the first 5days at HA were used to dichotomize participants according to AMS severity: moderate/severe AMS (AMS;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.